A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce

Joseph S. Friedberg, Melissa J. Culligan, Anne S. Tsao, Valerie Rusch, Boris Sepesi, Harvey I. Pass, Raphael Bueno, Bryan Burt, David J. Sugarbaker, Marc de Perrot, Alex Adjei, Prasad S. Adusumilli, Fred R. Hirsch, Shakuntala M. Malik, David J. Harpole

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although lung-sacrificing surgery for mesothelioma is fairly standardized, approaches to lung-sparing surgery are highly variable and lung sparing surgery is emerging internationally as the dominant extirpative procedure for this cancer. It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules. This article is an effort to address these problems by suggesting a more uniform approach to the surgical procedure and also proposing a series of data collection forms that could be adopted immediately, with any eye toward collecting the information that will be necessary to facilitate patient selection and determine which aspects of mesothelioma surgery can and should be standardized – with the goal being extension of life while maintaining quality of life as an equal priority. Furthermore, a completely original contribution in this manuscript is the proposal of a grading system that takes the information from the surgical procedure data forms and generates a completeness of resection score. This is the initial effort to establish a common denominator for mesothelioma surgery that will allow for more accurate comparison between surgical series and better assessment of the impact of the treatments combined with surgery.

Original languageEnglish (US)
Pages (from-to)1343-1353
Number of pages11
JournalJournal of Thoracic Oncology
Volume14
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Joints
Mesothelioma
Lung
Research
Neoplasms
Therapeutics
Patient Selection
Malignant Mesothelioma
Clinical Trials
National Cancer Institute (U.S.)
Advisory Committees
Standard of Care
Life Expectancy
Information Systems
Appointments and Schedules
Quality of Life
Recurrence

Keywords

  • Lung-sparing surgery
  • Malignant pleural mesothelioma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce. / Friedberg, Joseph S.; Culligan, Melissa J.; Tsao, Anne S.; Rusch, Valerie; Sepesi, Boris; Pass, Harvey I.; Bueno, Raphael; Burt, Bryan; Sugarbaker, David J.; de Perrot, Marc; Adjei, Alex; Adusumilli, Prasad S.; Hirsch, Fred R.; Malik, Shakuntala M.; Harpole, David J.

In: Journal of Thoracic Oncology, Vol. 14, No. 8, 01.08.2019, p. 1343-1353.

Research output: Contribution to journalReview article

Friedberg, Joseph S. ; Culligan, Melissa J. ; Tsao, Anne S. ; Rusch, Valerie ; Sepesi, Boris ; Pass, Harvey I. ; Bueno, Raphael ; Burt, Bryan ; Sugarbaker, David J. ; de Perrot, Marc ; Adjei, Alex ; Adusumilli, Prasad S. ; Hirsch, Fred R. ; Malik, Shakuntala M. ; Harpole, David J. / A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce. In: Journal of Thoracic Oncology. 2019 ; Vol. 14, No. 8. pp. 1343-1353.
@article{1e0e647112904ae2a9e3884cd9be044c,
title = "A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce",
abstract = "This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although lung-sacrificing surgery for mesothelioma is fairly standardized, approaches to lung-sparing surgery are highly variable and lung sparing surgery is emerging internationally as the dominant extirpative procedure for this cancer. It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules. This article is an effort to address these problems by suggesting a more uniform approach to the surgical procedure and also proposing a series of data collection forms that could be adopted immediately, with any eye toward collecting the information that will be necessary to facilitate patient selection and determine which aspects of mesothelioma surgery can and should be standardized – with the goal being extension of life while maintaining quality of life as an equal priority. Furthermore, a completely original contribution in this manuscript is the proposal of a grading system that takes the information from the surgical procedure data forms and generates a completeness of resection score. This is the initial effort to establish a common denominator for mesothelioma surgery that will allow for more accurate comparison between surgical series and better assessment of the impact of the treatments combined with surgery.",
keywords = "Lung-sparing surgery, Malignant pleural mesothelioma",
author = "Friedberg, {Joseph S.} and Culligan, {Melissa J.} and Tsao, {Anne S.} and Valerie Rusch and Boris Sepesi and Pass, {Harvey I.} and Raphael Bueno and Bryan Burt and Sugarbaker, {David J.} and {de Perrot}, Marc and Alex Adjei and Adusumilli, {Prasad S.} and Hirsch, {Fred R.} and Malik, {Shakuntala M.} and Harpole, {David J.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.jtho.2019.04.029",
language = "English (US)",
volume = "14",
pages = "1343--1353",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",

}

TY - JOUR

T1 - A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce

AU - Friedberg, Joseph S.

AU - Culligan, Melissa J.

AU - Tsao, Anne S.

AU - Rusch, Valerie

AU - Sepesi, Boris

AU - Pass, Harvey I.

AU - Bueno, Raphael

AU - Burt, Bryan

AU - Sugarbaker, David J.

AU - de Perrot, Marc

AU - Adjei, Alex

AU - Adusumilli, Prasad S.

AU - Hirsch, Fred R.

AU - Malik, Shakuntala M.

AU - Harpole, David J.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although lung-sacrificing surgery for mesothelioma is fairly standardized, approaches to lung-sparing surgery are highly variable and lung sparing surgery is emerging internationally as the dominant extirpative procedure for this cancer. It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules. This article is an effort to address these problems by suggesting a more uniform approach to the surgical procedure and also proposing a series of data collection forms that could be adopted immediately, with any eye toward collecting the information that will be necessary to facilitate patient selection and determine which aspects of mesothelioma surgery can and should be standardized – with the goal being extension of life while maintaining quality of life as an equal priority. Furthermore, a completely original contribution in this manuscript is the proposal of a grading system that takes the information from the surgical procedure data forms and generates a completeness of resection score. This is the initial effort to establish a common denominator for mesothelioma surgery that will allow for more accurate comparison between surgical series and better assessment of the impact of the treatments combined with surgery.

AB - This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although lung-sacrificing surgery for mesothelioma is fairly standardized, approaches to lung-sparing surgery are highly variable and lung sparing surgery is emerging internationally as the dominant extirpative procedure for this cancer. It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules. This article is an effort to address these problems by suggesting a more uniform approach to the surgical procedure and also proposing a series of data collection forms that could be adopted immediately, with any eye toward collecting the information that will be necessary to facilitate patient selection and determine which aspects of mesothelioma surgery can and should be standardized – with the goal being extension of life while maintaining quality of life as an equal priority. Furthermore, a completely original contribution in this manuscript is the proposal of a grading system that takes the information from the surgical procedure data forms and generates a completeness of resection score. This is the initial effort to establish a common denominator for mesothelioma surgery that will allow for more accurate comparison between surgical series and better assessment of the impact of the treatments combined with surgery.

KW - Lung-sparing surgery

KW - Malignant pleural mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=85069680129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069680129&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.04.029

DO - 10.1016/j.jtho.2019.04.029

M3 - Review article

C2 - 31136816

AN - SCOPUS:85069680129

VL - 14

SP - 1343

EP - 1353

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 8

ER -